William H Robinson1, Rong Mao. 1. aDivision of Immunology and Rheumatology, CCSR 4135, Stanford bGeriatric Research Education and Clinical Center, Veterans Affairs Palo Alto Healthcare System, Palo Alto, California, USA.
Abstract
PURPOSE OF REVIEW: The use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology. RECENT FINDINGS: Although significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain. SUMMARY: Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.
PURPOSE OF REVIEW: The use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology. RECENT FINDINGS: Although significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain. SUMMARY: Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.
Authors: William E O'Gorman; Elena W Y Hsieh; Erica S Savig; Pier Federico Gherardini; Joseph D Hernandez; Leo Hansmann; Imelda M Balboni; Paul J Utz; Sean C Bendall; Wendy J Fantl; David B Lewis; Garry P Nolan; Mark M Davis Journal: J Allergy Clin Immunol Date: 2015-05-30 Impact factor: 10.793
Authors: Rizi Ai; John W Whitaker; David L Boyle; Paul Peter Tak; Danielle M Gerlag; Wei Wang; Gary S Firestein Journal: Arthritis Rheumatol Date: 2015-07 Impact factor: 10.995
Authors: David S Gibson; Madeleine E Rooney; Sorcha Finnegan; Ji Qiu; David C Thompson; Joshua Labaer; Stephen R Pennington; Mark W Duncan Journal: Rheumatology (Oxford) Date: 2011-12-16 Impact factor: 7.580
Authors: Rae S M Yeung; Salvatore Albani; Brian M Feldman; Elizabeth Mellins; Berent Prakken; Lucy R Wedderburn Journal: Nat Rev Rheumatol Date: 2016-09-22 Impact factor: 20.543
Authors: Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester Journal: Arthritis Res Ther Date: 2020-06-10 Impact factor: 5.156
Authors: Michael J Grayling; Theophile Bigirumurame; Svetlana Cherlin; Luke Ouma; Haiyan Zheng; James M S Wason Journal: BMC Rheumatol Date: 2021-07-02
Authors: Amalia Lamana; Ricardo Villares; Iria V Seoane; Nuria Andrés; Pilar Lucas; Paul Emery; Edward M Vital; Ana Triguero-Martínez; Ana Marquez; Ana M Ortiz; Robin Maxime; Carmen Martínez; Javier Martín; Rosa P Gomariz; Frederique Ponchel; Isidoro González-Álvaro; Mario Mellado Journal: Front Immunol Date: 2020-06-26 Impact factor: 8.786